{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:31:32Z","timestamp":1775205092945,"version":"3.50.1"},"reference-count":24,"publisher":"BMJ","issue":"8","funder":[{"name":"Jim Pullin Trust"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,7,29]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term. However, information is lacking on patients\u2019 perspectives on such effects. Studying these can contribute to greater understanding of the mechanisms underlying impact of ketamine treatment on SI. The aim of this study was to investigate patients\u2019 reports of the impact of treatment on their SI, the duration of effects and possible mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>This qualitative study consisted of semi-structured interviews with patients who had received ketamine treatment for depression. Interview data were analysed thematically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Fourteen patients (8 females, 6 males, aged 24\u201364 years) who had received treatment with ketamine for treatment-resistant depression, and had SI at the initiation of treatment. Two participants also had a diagnosis of bipolar type 1 and two of emotionally unstable personality disorder. Eight had a history of self-harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SI reduced following ketamine treatment in 12 out of 14 participants for periods of a few hours following a single treatment to up to three\u2009years with ongoing treatment. Reduction of SI was variable in terms of extent and duration, and re-emergence of suicidal thoughts often occurred when treatment ceased. Participants\u2019 accounts indicated that reduced SI was associated with improved mood and reduced anxiety, as were clarity of thought, focus and concentration, and ability to function. Participants reported experiencing some or all of these effects in various orders of occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Generally, ketamine treatment was experienced as effective in reducing SI, although duration of effects varied considerably. Patients\u2019 perspectives indicated similarities in the mechanisms of reduction in SI, but some differences in their manifestation, particularly in relation to chronology. Experiences of this cohort suggest that reduced anxiety and improvement in ability to think and function were important mechanisms alongside, or in some cases independently of, improvement in mood. Further studies of patients\u2019 experiences are required to gain enhanced understanding of the variability of effects of ketamine on SI and functionality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-029108","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T03:46:02Z","timestamp":1565927162000},"page":"e029108","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Effects of ketamine treatment on suicidal ideation: a qualitative study of patients\u2019 accounts following treatment for depression in a UK ketamine clinic"],"prefix":"10.1136","volume":"9","author":[{"given":"Karen","family":"Lascelles","sequence":"first","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"},{"name":"Department of Psychiatry, Centre for Suicide Research, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Marzano","sequence":"additional","affiliation":[{"name":"Department of Psychology, Middlesex University, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Brand","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"},{"name":"Department of Psychiatry, Centre for Suicide Research, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Trueman","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Rupert","family":"McShane","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"},{"name":"Cochrane Dementia and Cognitive Improvement Group (CDCIG), Nuffield Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4985-5715","authenticated-orcid":false,"given":"Keith","family":"Hawton","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"},{"name":"Department of Psychiatry, Centre for Suicide Research, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2025121604254741000_9.8.e029108.1","unstructured":"World Health Organization . Preventing suicide: a global imperative. World Health Organization, 2014."},{"key":"2025121604254741000_9.8.e029108.2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702006943"},{"key":"2025121604254741000_9.8.e029108.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00702.x"},{"key":"2025121604254741000_9.8.e029108.4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2215-0366(16)30030-X","article-title":"Suicide prevention strategies revisited: 10-year systematic review","volume":"3","author":"Zalsman","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025121604254741000_9.8.e029108.5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1192\/bjp.2018.56","article-title":"We all know what we mean by treatment-resistant depression \u2013 don't we?","volume":"212","author":"Anderson","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2025121604254741000_9.8.e029108.6","doi-asserted-by":"crossref","unstructured":"Caddy C , Amit BH , McCloud TL , et al . Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015;75.doi:10.1002\/14651858.CD011612.pub2","DOI":"10.1002\/14651858.CD011612.pub2"},{"key":"2025121604254741000_9.8.e029108.7","doi-asserted-by":"crossref","unstructured":"McCloud TL , Caddy C , Jochim J , et al . Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015;14.doi:10.1002\/14651858.CD011611.pub2","DOI":"10.1002\/14651858.CD011611.pub2"},{"key":"2025121604254741000_9.8.e029108.8","doi-asserted-by":"publisher","DOI":"10.1177\/0004867413486842"},{"key":"2025121604254741000_9.8.e029108.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.05.010"},{"key":"2025121604254741000_9.8.e029108.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102888","article-title":"Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors","volume":"19","author":"De Berardis","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025121604254741000_9.8.e029108.11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neubiorev.2017.03.010","article-title":"Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis","volume":"77","author":"Bartoli","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"2025121604254741000_9.8.e029108.12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2025121604254741000_9.8.e029108.13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"AJP"},{"key":"2025121604254741000_9.8.e029108.14","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0232-4"},{"key":"2025121604254741000_9.8.e029108.15","doi-asserted-by":"publisher","DOI":"10.1002\/da.22253"},{"key":"2025121604254741000_9.8.e029108.16","doi-asserted-by":"crossref","unstructured":"Phillips JL , Norris S , Talbot J , et al . Direct effect of ketamine on suicidal ideation independent of its effects on depressive symptoms. Eur Neuropsychopharmacol 2016;26.doi:10.1016\/S0924-977X(16)31473-0","DOI":"10.1016\/S0924-977X(16)31473-0"},{"key":"2025121604254741000_9.8.e029108.17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2017.04.057","article-title":"Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials","volume":"218","author":"Ballard","year":"2017","journal-title":"J Affect Disord"},{"key":"2025121604254741000_9.8.e029108.18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2018.07.077","article-title":"Characterizing the course of suicidal ideation response to ketamine","volume":"241","author":"Ballard","year":"2018","journal-title":"J Affect Disord"},{"key":"2025121604254741000_9.8.e029108.19","unstructured":"Beck AT , Schuyler D , Herman I . Development of suicidal intent scales. in: the prediction of suicide. Philadelphia, PA: Charles Press, 1974: 45\u201356."},{"key":"2025121604254741000_9.8.e029108.20","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121604254741000_9.8.e029108.21","doi-asserted-by":"crossref","unstructured":"Xu Y , Hackett M , Carter G , et al . Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. IJNPPY 2016;19.doi:10.1093\/ijnp\/pyv124","DOI":"10.1093\/ijnp\/pyv124"},{"key":"2025121604254741000_9.8.e029108.22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"AJP"},{"key":"2025121604254741000_9.8.e029108.23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05327blu"},{"key":"2025121604254741000_9.8.e029108.24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.7205\/MILMED-D-15-00431","article-title":"A double-blinded, randomized, placebo-controlled Sub-Dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting","volume":"181","author":"Burger","year":"2016","journal-title":"Mil Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-029108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:25:57Z","timestamp":1765887957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-029108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,15]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjopen-2019-029108"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-029108","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}